Stockreport

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology SA - American Depositary Shares  (CYAD) 
US:NASDAQ Investor Relations: celyad.com/en/investors
PDF MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the disc [Read more]